COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02495103
Recruitment Status : Completed
First Posted : July 13, 2015
Last Update Posted : April 20, 2020
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )

Brief Summary:


- There are no established treatments for people with certain advanced kidney cancers. These tumors often don t respond well to currently available treatments. Researchers believe that two drugs that treat other diseases metformin and vandetanib could help people with advanced kidney cancer.


- To test the combination of metformin and vandetanib in people with advanced kidney cancer. Phase I of the study will determine a safe dose for the drugs. Phase II will test this dose in people with certain kidney cancers.


  • For Phase I, people 18 and over with advanced kidney cancer
  • For Phase II, people 18 and over with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC), succinate dehydrogenase renal cell carcinoma (SDH-RCC), or advanced papillary renal cell carcinoma not related to a hereditary syndrome


  • The study will last many months.
  • Participants will be screened with medical history and physical exam.
  • Participants will take the study drugs by mouth every day.
  • Participants will measure and record their blood pressure every day.
  • Participants will have many tests:
  • Blood and urine tests
  • MRI, CT, PET scan, and other imaging tests: they will lie in machines that take pictures of their body.
  • ECG: soft electrodes will be stuck to the skin. A machine will record the heart s signals.
  • Bone scan
  • Some participants may have a gynecology evaluation or photos of skin tumors taken.
  • Participants will have an optional tumor biopsy.
  • After they stop taking the drugs, participants may have medical history, physical exam, and blood tests. They will be contacted once a year by phone to find out how they are doing.

Condition or disease Intervention/treatment Phase
Renal Cell Carcinoma Hereditary Leiomyomatosis Renal Cell Cancer Drug: Vandetanib Drug: Metformin Drug: Vandetanib/Metformin Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Actual Study Start Date : August 26, 2015
Actual Primary Completion Date : February 6, 2020
Actual Study Completion Date : February 6, 2020

Arm Intervention/treatment
Experimental: 1
Phase I Component
Drug: Vandetanib
PHASE I: Vandetanib PO daily at 300mg in combination with escalating doses of metformin.

Drug: Metformin
Phase I: Metformin starting dose 250mg PO daily in combination with Vandetanib

Experimental: 2
Phase II Component
Drug: Vandetanib/Metformin
Phase II: Vandetanib and metformin PO daily at determined MTD.

Primary Outcome Measures :
  1. Phase 1 Component: To establish the safety and maximum tolerated dose (MTD) of vandetanib and metformin when used in combination in patients with metastatic RCC. [ Time Frame: 42 days after the last patient starts therapy. ]
    List of adverse events frequency and MTD

  2. Phase 2 Component: To determine the overall response rate (RECIST 1.1) following treatment with the combination of vandetanib and metformin in patients with 1) advanced RCC associated with HLRCC or SDH, and 2) advanced sporadic/non-HLRCC papilla... [ Time Frame: 3 years after the last patient finishes therapy. ]
    Percentage of patients who have a response to therapy.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

    1. Diagnosis/Histology

      1. Phase I Component Histologically confirmed advanced RCC of any subtype.
      2. Phase II Component Advanced RCC associated with 1) HLRCC or SDH (Cohort 1); OR 2) advanced non HLRCC-related papillary RCC (Cohort 2).
    2. Phase 1: Patients must have evaluable disease

Phase 2: Patients must have measurable disease based on RECIST 1.1 criteria, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as >20 mm with conventional techniques or as >10 mm with spiral CT scan or MRI (except for lymph nodes, which must be >15 mm).

3. Prior Therapy

  1. Phase 1- Patients with clear cell RCC must have either declined, be ineligible to receive, have progressed on, or be intolerant to high dose IL-2, or standard first and second line VEGF, or mTOR targeted agents. As there is no standard therapy for metastatic non-clear cell RCC, no prior therapy is required.
  2. Phase 2- No more than two prior VEGF-pathway targeted agents
  3. No previous treatment with vandetanib. Previous or ongoing treatment with metformin is allowed.

    4. Age greater than or equal to18 years.

    5. ECOG performance status <2 (Karnofsky >60%).

    6. Negative pregnancy test (urine or serum) for female patients of childbearing potential.

    7. Patients must have normal organ and marrow function as defined below:

    absolute neutrophil count greater than or equal to 1,500/mcL

    platelets greater than or equal to 100,000/mcL

    total bilirubin less than or equal to 1.5x upper limit of reference range ( < 3x upper limit of reference range in patients with Gilbert s disease)

    AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of normal

    eGFR (CKD-EPI) greater than or equal to 50 mL/min/1.73 m2

    8. Men and women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation and for at least 6 months after vandetanib/metformin therapy. Should a woman become pregnant (either a participant or the partner of a male participant) or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.

    9. Ability of subject to understand and the willingness to sign a written informed consent document.


    1. Known serious allergic reaction to vandetanib or metformin.
    2. Brain metastases or spinal cord compression that requires treatment, unless the treatment ended at least 4 weeks before starting protocol therapy and the condition has been stable without steroid treatment for at least 10 days.
    3. Major surgery (includes any surgery that carries significant risk of blood loss, extended periods of general anesthesia, or requires at least an overnight hospital admission) within 28 days before starting treatment or inadequately healed incision/scar from prior surgery.
    4. Any unresolved chronic toxicity greater than Common Terminology Criteria for Adverse Event (CTCAE) Grade 2 or greater from previous anti-cancer therapy (this criterion does not apply to alopecia).
    5. Unacceptable electrolyte values, including:

      • Potassium <4.0 mmol/L despite supplementation, or elevated potassium above the CTCAE Grade 1 upper limit.
      • Magnesium below the lower limit of normal range despite supplementation, or elevated magnesium above the CTCAE Grade 1 upper limit.
      • Ionized calcium or corrected calcium values below the normal range or hypercalcemia above the CTCAE Grade 1 upper limit.
    6. Significant cardiac event (eg, myocardial infarction), New York Heart Association (NYHA) classification of heart disease greater than or equal to 2 within 12 weeks before starting treatment, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
    7. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia), which is symptomatic or requires treatment (CTCAE Grade 3), symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Patients with atrial fibrillation controlled by medication are permitted.
    8. Hypertension not controlled by medical therapy (systolic blood pressure greater than 140 millimeter of mercury [mmHg] or diastolic blood pressure greater than 90 mmHg).
    9. Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.
    10. Proteinuria > 1gram/24 hrs
    11. Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator s opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
    12. Previous or current invasive malignancies of other histologies requiring treatment within the last 2 years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin (phase 2 only).

    13 Congenital long QT syndrome.

    14 Any concomitant medications that are known to be associated with Torsades de Pointes Drugs that in the investigator s opinion cannot be discontinued, are allowed however, must be monitored closely

    15 .Any concomitant potent inducers of cytochrome P450 3A4 (CYP3A4) function (see for a continually updated list of CYP3A4 inducers).

    16 History of QT prolongation associated with other medications that required discontinuation of that medication.

    17 QTcF correction unmeasurable or >450 ms on screening ECG (Note: If a patient has a QTcF interval >450 ms on screening ECG, the screening ECG may be repeated twice [at least 24 hours apart] for a total of 3 ECGs. The average QTcF from the three

    screening ECGs must be less than or equal to 450 ms in order for the patient to be eligible for the study).

    18. Women that are currently breast feeding.

    19. Active treatment-refractory diarrhea that may affect the ability of the patient to absorb the trial agents or tolerate further diarrhea.

    20. HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vandetanib/metformin.

    21. Patients with active hemoptysis, clinically significant non hemorrhoidal GI bleeding or those with bleeding diathesis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02495103

Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Ramaprasad Srinivasan, M.D. National Cancer Institute (NCI)
Additional Information:
Layout table for additonal information
Responsible Party: National Cancer Institute (NCI) Identifier: NCT02495103    
Other Study ID Numbers: 150157
First Posted: July 13, 2015    Key Record Dates
Last Update Posted: April 20, 2020
Last Verified: March 9, 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) ):
Maximum Tolerated Dose
Overall Response
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Renal Cell
Kidney Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Neoplasms, Muscle Tissue
Neoplasms, Connective and Soft Tissue
Hypoglycemic Agents
Physiological Effects of Drugs